论文部分内容阅读
目的探讨紧密连接蛋白-1(ZO-1)基因启动子区甲基化状态在非霍奇金淋巴瘤(NHL)检测中的临床意义。方法采用甲基化特异性PCR方法(MS-PCR)分析10例非血液系统肿瘤者骨髓及45例NHL患者骨髓标本的ZO-1基因启动子区甲基化状况。结果ZO-1基因在10例良性血液病及正常人中呈完全非甲基化状态,在39例初治、复发、未完全缓解的淋巴瘤患者中甲基化阳性率53.85%(P<0.05)。在39例初治或复发或未达到完全缓解的NHL患者中28例Ⅲ、Ⅳ期的NHL患者ZO-1基因甲基化阳性率64.29%,11例Ⅰ、Ⅱ期的NHL患者ZO-1基因甲基化阳性率27.27%(P<0.05)。初治、复发患者28例中甲基化阳性16例(57.14%),经治疗达到部分缓解的11例患者中甲基化阳性5例(45.45%),临床缓解的6例患者均为完全非甲基化。结论ZO-1基因启动子区高甲基化与疾病分期及缓解明显相关,它可以作为判断NHL进展和评价预后的辅助指标,并以此指导临床治疗。
Objective To investigate the clinical significance of methylation status of promoter region of tight junction protein-1 (ZO-1) gene in non-Hodgkin’s lymphoma (NHL). Methods Methylation-specific PCR (MS-PCR) was used to analyze the methylation status of ZO-1 promoter in bone marrow of 10 patients with non-hematologic malignancies and 45 patients with NHL. Results The ZO-1 gene was completely unmethylated in 10 patients with benign hematological diseases and normal controls. The positive rate of methylation was 53.85% (39.05%) in 39 patients with newly diagnosed, relapsed and not completely relieved lymphoma (P <0.05) ). The methylation positive rate of ZO-1 gene was 28.29% in 28 NHL patients with stage III and IV NHR in 39 newly diagnosed or relapsed or non-relapsed NHL patients, and 11 cases of NHL patients with stage I and II ZO-1 gene methylation The positive rate of methylation was 27.27% (P <0.05). Of the 28 newly diagnosed and relapsed patients, methylation was positive in 16 (57.14%) of the 28 patients, 5 (45.45%) were methylated in 11 of the 11 patients who achieved partial remission, and 6 of the 6 patients with complete remission Methylation. Conclusion The hypermethylation of ZO-1 gene promoter region is significantly associated with the stage and mitigation of disease. It can be used as a secondary indicator to judge the progression of NHL and to evaluate the prognosis, and to guide the clinical treatment.